- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ENTEST GROUP Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| NOVAVAX | 8,226 | +1,56 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,990 | +0,34 % | HEIDELBERG PHARMA AG - Schwäche mit Signalwirkung | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,620 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,844 | +1,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,105 | -0,37 % | Sarepta Therapeutics Stock Jumps 7% On Positive Phase 3 Three-Year Data For ELEVIDYS | ||
| EXELIXIS | 36,810 | +0,30 % | Exelixis: Diese Pharma-Aktie hat mehr Aufmerksamkeit verdient! | Die Aktie von Exelixis steht trotz operativ starker Entwicklung und attraktiver Kennzahlen bislang nicht im Rampenlicht vieler Investoren. Dabei bietet das Papier eines schuldenfreien Biopharmaunternehmens... ► Artikel lesen | |
| GERON | 1,153 | +0,30 % | Geron Corporation Provides 2026 Financial Guidance | 2026 RYTELO (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,378 | -1,52 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,625 | +0,81 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| XOMA ROYALTY | 21,800 | -2,68 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| PALISADE BIO | 1,820 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 | PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 29,600 | +2,78 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| AMICUS THERAPEUTICS | 12,000 | +0,84 % | AMICUS THERAPEUTICS, INC. - 8-K, Current Report |
Das Unternehmen ENTEST GROUP INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENTEST GROUP INC finden Sie auf Wallstreet Online.